Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167295 | 1.00 | FGFR4 (0.43) | FGFR4KCNJ1CCR1HDAC8ALDH1A1 | |
| SCHEMBL454403 | 0.79 | ALDH1A1 (0.42) | FGFR4KCNJ1CCR1ALDH1A1EGLN2 | |
| SCHEMBL12750930 | 0.78 | HDAC8 (0.32) | FGFR4HDAC8KEAP1 | |
| SCHEMBL18810357 | 0.76 | MAPT (0.38) | FGFR4KCNJ1CCR1ALDH1A1PARP1 | |
| SCHEMBL28715229 | 0.76 | KDM4E (0.42) | FGFR4HDAC8CA12CA1CA2 | |
| SCHEMBL29426368 | 0.76 | KDM4E (0.42) | FGFR4HDAC8CA12CA1CA2 | |
| SCHEMBL28715082 | 0.76 | KDM4E (0.42) | FGFR4HDAC8CA12CA1CA2 | |
| SCHEMBL29426373 | 0.76 | KDM4E (0.42) | FGFR4HDAC8CA12CA1CA2 | |
| SCHEMBL28536669 | 0.75 | FFAR1 (0.47) | — | |
| SCHEMBL578670 | 0.73 | KCNJ1 (0.35) | KCNJ1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437350-A | Polyimide resin and preparation method and application thereof | 波米科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114315686-A | Alkynyl-containing diamine, preparation method thereof and application thereof in preparation of photosensitive resin composition | 波米科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20240382465-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-111285873-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024153173-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4382527-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-05-14 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| CN-116133658-A | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2023-05-16 | — | — | CN | disclosed |
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382465-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, ACAD11, ACOX1 | FGFR4 3237/4885KCNJ1 997/4885CCR1 2276/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | FGFR4 423/4885KCNJ1 2402/4885CCR1 4660/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | FGFR4 384/4885KCNJ1 2108/4885CCR1 4725/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | FGFR4 423/4885KCNJ1 2402/4885CCR1 4660/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | FGFR4 2751/4885KCNJ1 3800/4885CCR1 3849/4885 |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | FGFR4 116/4885KCNJ1 2783/4885CCR1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.